Anti–claudin-1 (CLDN1) monoclonal antibody intended to inhibit CLDN1-driven pro-tumor signaling and invasion and enable immune effector engagement against CLDN1-positive cells.
Humanized anti-CLDN1 monoclonal antibody that binds an extracellular epitope on non-junctional CLDN1 on tumor cells, blocks CLDN1-driven pro-tumor signaling and ECM remodeling to improve immune-cell infiltration, and engages Fc effector functions to mediate ADCC, promoting NK- and T-cell-mediated killing of CLDN1-positive cells.
YES
DIRECT
Anti-CLDN1 mAb binds non-junctional CLDN1 on tumor cells and, via its Fc region, recruits FcγR+ immune effectors to mediate ADCC (e.g., NK cell–mediated lysis) of CLDN1-positive cells.
Autologous anti-BCMA CAR T-cell therapy (engineered T cells targeting BCMA on myeloma cells).
Autologous T cells engineered with a BCMA-targeting chimeric antigen receptor (dual-epitope binder with 4-1BB costimulatory domain). After infusion, CAR T cells bind BCMA on malignant plasma cells, activate, expand, and induce targeted cytotoxicity against BCMA-expressing tumor cells.
YES
DIRECT
Anti-BCMA CAR T cells bind BCMA on target cells, activate, and kill them via T cell cytotoxic mechanisms (perforin/granzyme-mediated apoptosis and related death receptor pathways).
GPRC5D×CD3 bispecific T-cell–redirecting antibody that engages T cells to kill myeloma cells expressing GPRC5D.
Humanized bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells, cross-linking them to activate cytotoxic T cells and induce perforin/granzyme-mediated lysis of GPRC5D-expressing tumor cells.
YES
DIRECT
Talquetamab bridges CD3 on T cells to GPRC5D on target cells, activating T cells to kill GPRC5D-expressing cells via perforin/granzyme-mediated cytolysis.
GPRC5D×CD3 bispecific T-cell–redirecting antibody that engages T cells to kill myeloma cells expressing GPRC5D.
Humanized bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells, cross-linking them to activate cytotoxic T cells and induce perforin/granzyme-mediated lysis of GPRC5D-expressing tumor cells.
NO
INDIRECT
Talquetamab binds CD3 on T cells and GPRC5D on myeloma cells to crosslink and activate T cells, which kill GPRC5D+ tumor cells via perforin/granzyme; CD3+ T cells are not targeted for killing.
Anti-CD38 monoclonal antibody mediating ADCC, CDC, and phagocytosis against myeloma cells.
Human IgG1 kappa anti-CD38 monoclonal antibody that binds CD38 on myeloma and other CD38+ cells, inducing Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct apoptosis; depletes CD38+ tumor cells and CD38-expressing immunosuppressive cells, enhancing antitumor immunity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and triggers NK cell–mediated ADCC, macrophage ADCP, complement-dependent cytotoxicity (CDC), and can induce direct apoptosis.